Advertisement

Topics

Intravenous fosfomycin for the treatment of multidrug resistant pathogens: what is the evidence on dosing regimens?

07:00 EST 22nd January 2019 | BioPortfolio

Summary of "Intravenous fosfomycin for the treatment of multidrug resistant pathogens: what is the evidence on dosing regimens?"

The intravenous (IV) formulation of fosfomycin has been re-introduced lately in clinical practice mainly to overcome treatment failures against multi drug-resistant (MDR), bacterial strains. However, appropriate dosing schedules of the IV formulation of the drug have not yet been established. Areas covered: The mechanism of action and resistance development, commercial IV formulations, pharmacokinetic/pharmacodynamics (PK/PD) properties, IV dosing regimens commonly used for the treatment of MDR infections along with efficacy and safety issues were reviewed. Data regarding specific MDR pathogens with emphasis on daily doses and patients' outcomes, gaps in the current literature, as well as, in progress research agenda are presented. Expert opinion: The doses of fosfomycin IV range between 12-24 grams/day depending on the severity of infection. The efficacy and safety of the commonly administered doses have been shown mainly in observational non-comparative trials. The optimal dose ensuring maximal efficacy with minimal toxicity along with the most appropriate co-administered antibiotic(s) needs further evaluation. The pharmacokinetic/pharmacodynamic (PK/PD) parameter associated with fosfomycin maximum efficacy has not yet been established, although, the ratio of the area under the concentration-time curve (AUC) for the free unbound fraction of fosfomycin versus the MIC (fAUC/MIC) may be linked to optimal treatment. Future research agenda should focus on these gaps of knowledge. RCTs and other comparative studies are needed to establish appropriate doses, intervals and combination selections. Four registered clinical trials are underway to address these issues in adult patients while a randomized interventional trial including a pharmacokinetic study in hospitalized neonates with clinical sepsis (Neofosfo trial) will be terminated soon.

Affiliation

Journal Details

This article was published in the following journal.

Name: Expert review of anti-infective therapy
ISSN: 1744-8336
Pages:

Links

DeepDyve research library

PubMed Articles [27908 Associated PubMed Articles listed on BioPortfolio]

High rate of colistin and fosfomycin resistance among carbapenemase-producing Enterobacteriaceae in Turkey.

When the problem with carbapenem-resistant Enterobacteriaceae (CRE) increases, the older antimicrobial agents such as colistin and fosfomycin are used for the treatment of these infections. In this st...

Best tigecycline dosing for treatment of infections caused by multidrug-resistant pathogens in critically ill patients with different body weights.

The intensive care unit (ICU) is a center of multidrug-resistant (MDR) pathogens. This is due to overuse of antibiotics in the treatment of critically ill patients. Tigecycline is a broad-spectrum ant...

Fosfomycin for injection (ZTI-01) vs Piperacillin-Tazobactam (PIP-TAZ) for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP): ZEUS, A Phase 2/3 Randomized Trial.

ZTI-01 (fosfomycin for injection) is an epoxide antibiotic with a differentiated mechanism of action (MOA) inhibiting an early step in bacterial cell wall synthesis. ZTI-01 has broad in vitro spectrum...

Resistance to fosfomycin: Mechanisms, Frequency and Clinical Consequences.

Fosfomycin has been used for the treatment of infections due to susceptible and multi-drug resistant (MDR) bacteria. It inhibits bacterial cell wall synthesis at a step prior to that of β-lactams thr...

Risk stratification and treatment of ICU-acquired pneumonia caused by multidrug- resistant/extensively drug-resistant/pandrug-resistant bacteria.

Describe the risk factors and discuss the management of multidrug-resistant (MDR) bacteria responsible for pneumonia among critically ill patients, including methicillin-resistant Staphylococcus aureu...

Clinical Trials [7498 Associated Clinical Trials listed on BioPortfolio]

PK/PD and Safety/Tolerability of Three Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adults

Oral dosage regimens for fosfomycin tromethamine (Monurol™) are not established for the treatment of cUTI. The most common and recommended adult dosage regimen in the literature is a sin...

Fosfomycin Plus Imipenem for Treatment of Infective Endocarditis

The study evaluates the efficacy and safety of fosfomycin and imipenem for the treatment of methicillin-resistant staphyloccocus aureus infective endocarditis in comparison to vancomycin, ...

Efficacy and Safety of Intravenous Fosfomycin in Prosthetic Joint Infection

The PROOF Study is an open prospective interventional non-randomized study which aim is to determine the outcome / effect and safety of fosfomycin in patients with hip, knee or shoulder PJ...

Study of S-649266 or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens

This study is designed to provide evidence of efficacy of S-649266 in the treatment of serious infections in adult patients caused by carbapenem-resistant Gram-negative pathogens.

Intraperitoneal Administration of Fosfomycin, Metronidazole and Molgramostim Versus Intravenous Antibiotics for Perforated Appendicitis

The objective of this trial is to evaluate if intraoperative intraperitoneal administration of fosfomycin, metronidazole and recombinant human granulocyte-macrophage colony-stimulating fac...

Medical and Biotech [MESH] Definitions

Tuberculosis resistant to chemotherapy with two or more ANTITUBERCULAR AGENTS, including at least ISONIAZID and RIFAMPICIN. The problem of resistance is particularly troublesome in tuberculous OPPORTUNISTIC INFECTIONS associated with HIV INFECTIONS. It requires the use of second line drugs which are more toxic than the first line regimens. TB with isolates that have developed further resistance to at least three of the six classes of second line drugs is defined as EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS.

An approach or process of practicing oral health care that requires the judicious integration of systematic assessments of clinical relevant scientific evidence, relating to the patient's oral and medical condition and history, with the dentist's clinical expertise and the patient's treatment needs and preferences. (from J Am Dent Assoc 134: 689, 2003)

An antibiotic produced by Streptomyces fradiae.

Strains of the genus Enterococcus that are resistant to the antibiotic VANCOMYCIN. The enterococci become resistant by acquiring plasmids carrying genes for VANCOMYCIN RESISTANCE.

An approach of practicing medicine with the goal to improve and evaluate patient care. It requires the judicious integration of best research evidence with the patient's values to make decisions about medical care. This method is to help physicians make proper diagnosis, devise best testing plan, choose best treatment and methods of disease prevention, as well as develop guidelines for large groups of patients with the same disease. (from JAMA 296 (9), 2006)

Advertisement
Quick Search
Advertisement
Advertisement

 


DeepDyve research library

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...


Searches Linking to this Article